Gilead to Acquire Ouro Medicines to Expand Autoimmune Portfolio

Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines, a privately held firm focused on developing T cell engager therapies for autoimmune diseases. The move marks a strategic expansion of Gilead’s inflammation and immunology pipeline as it seeks to advance next-generation treatments for serious immune-mediated conditions.

The acquisition brings with it OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager that has shown promising early results in treating severe autoimmune disorders. The therapy is designed to deliver rapid and deep depletion of B cells through a limited course of subcutaneous administration, potentially offering durable disease control without the need for continuous treatment.

Gamgertamig is currently being evaluated in Phase 1/2 clinical trials and has demonstrated encouraging efficacy and safety following a single treatment cycle. The investigational therapy is being studied in rare, antibody-mediated diseases such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Notably, it has received both Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration for these indications, highlighting its potential to address significant unmet medical needs. The therapy is expected to progress into registrational studies by 2027.

According to Dietmar Berger, the acquisition underscores Gilead’s commitment to developing transformative therapies for patients with serious autoimmune diseases. He emphasized that targeting B-cell maturation antigen (BCMA) represents a promising approach, with emerging data suggesting the potential for meaningful and lasting clinical outcomes.

BCMA-targeted T cell engagers are being explored as a precision therapy that redirects a patient’s immune system to eliminate disease-causing plasma cells. Early research indicates that this approach could reduce inflammation, improve organ function, and potentially reset the immune system, leading to sustained remission without ongoing immunosuppression. This mechanism complements Gilead’s broader portfolio, which also includes chimeric antigen receptor T-cell (CAR-T) therapies.

Jaideep Dudani expressed confidence that the acquisition will accelerate the development of gamgertamig. He noted that Gilead’s expertise in late-stage development, regulatory approval, and commercialization will help bring the therapy closer to patients. The program has already advanced through multiple clinical studies, supported by prior collaborations with industry partners.

The deal reflects a broader industry trend toward investing in innovative immunotherapies that can address complex autoimmune diseases with high unmet need. By integrating Ouro’s pipeline and expertise, Gilead aims to strengthen its position in the rapidly evolving field of immunology and deliver potentially groundbreaking treatment options for patients worldwide.